Choosing antithrombotics for atrial fibrillation in primary care.
作者信息
Mustafa Mohammed, Sheppard James P
机构信息
Grange Medical Practice, Cardiff, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford; Senior Fellow, National Institute for Health Research, Oxford Biomedical Research Centre, UK.
出版信息
Br J Gen Pract. 2020 Feb 27;70(692):102-103. doi: 10.3399/bjgp20X708317. Print 2020 Mar.
Abstract
摘要
相似文献
1
Choosing antithrombotics for atrial fibrillation in primary care.在基层医疗中为心房颤动选择抗栓药物。
Br J Gen Pract. 2020 Feb 27;70(692):102-103. doi: 10.3399/bjgp20X708317. Print 2020 Mar.
2
Atrial fibrillation and stroke.心房颤动与中风。
Cerebrovasc Dis. 2000;10 Suppl 4:40-1. doi: 10.1159/000047593.
3
Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey.心房颤动卒中预防指南与基层医疗实践模式之间的差异。法国全国性AFIGP调查。
Arch Cardiovasc Dis. 2015 Nov;108(11):544-53. doi: 10.1016/j.acvd.2015.05.005. Epub 2015 Jun 22.
4
Audit, antithrombotics and atrial fibrillation--going full circle.审计、抗栓治疗与心房颤动——循环往复。
Age Ageing. 2002 Sep;31(5):327-8. doi: 10.1093/ageing/31.5.327.
5
AHA/ASA publish advisory on oral antithrombotics for stroke prevention in nonvalvular artial fibrillation.美国心脏协会/美国卒中协会发布关于非瓣膜性心房颤动患者预防卒中的口服抗栓药物的咨询意见。
Am Fam Physician. 2013 May 15;87(10):732-3.
6
Viewpoint: management of atrial fibrillation.观点：心房颤动的管理
Circulation. 2006 Aug 15;114(7):f126-7.
7
[Adherence to the rules for antithrombotic treatment in atrial fibrillation].[心房颤动抗栓治疗的规则依从性]
Rev Med Liege. 2010 May-Jun;65(5-6):299-303.
8
Antithrombotic therapies for stroke prevention in atrial fibrillation.用于心房颤动中风预防的抗栓治疗。
Adv Neurol. 2003;92:249-56.
9
[Prevention of stroke in atrial fibrillation].[心房颤动患者的卒中预防]
Neurologia. 2012 Mar;27 Suppl 1:1-3. doi: 10.1016/S0213-4853(12)70001-4.
10
Atrial fibrillation subtypes, risk of stroke, and antithrombotic therapy.心房颤动亚型、中风风险与抗血栓治疗。
Eur Heart J. 2008 Apr;29(7):840-2. doi: 10.1093/eurheartj/ehm594. Epub 2008 Mar 10.
引用本文的文献
1
Awareness of Varicose Veins Associated With the Use of Contraceptive Pills Among Women in Jazan, Saudi Arabia: A Cross-Sectional Study.沙特阿拉伯吉赞地区女性中与使用避孕药相关的静脉曲张认知：一项横断面研究
Cureus. 2025 Jan 4;17(1):e76912. doi: 10.7759/cureus.76912. eCollection 2025 Jan.
本文引用的文献
1
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.心房颤动合并稳定性冠心病的抗栓治疗。
N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.
2
Safety and Effectiveness of Contemporary P2Y Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population-Based Cohort Study.当代 P2Y12 抑制剂在东亚急性冠状动脉综合征人群中的安全性和有效性：一项全国范围内基于人群的队列研究。
J Am Heart Assoc. 2019 Jul 16;8(14):e012078. doi: 10.1161/JAHA.119.012078.
3
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.直接口服抗凝剂与华法林在真实世界环境中的风险和获益：初级保健中的队列研究。
BMJ. 2018 Jul 4;362:k2505. doi: 10.1136/bmj.k2505.
4
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
5
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.口服抗凝药预防心房颤动患者卒中：系统评价、网状Meta分析及成本效益分析
BMJ. 2017 Nov 28;359:j5058. doi: 10.1136/bmj.j5058.
6
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界环境中比较非维生素 K 拮抗剂口服抗凝药与维生素 K 拮抗剂预防心房颤动卒中：系统评价和荟萃分析。
Stroke. 2017 Sep;48(9):2494-2503. doi: 10.1161/STROKEAHA.117.017549. Epub 2017 Jul 17.
7
Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.非瓣膜性心房颤动患者口服抗凝治疗的依从性：维生素 K 拮抗剂与非维生素 K 拮抗剂的比较。
Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):151-156. doi: 10.1093/ehjcvp/pvw048.
8
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
9
Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.华法林或新型口服抗凝药治疗新诊断非瓣膜性心房颤动的治疗持续性：一项队列研究。
Thromb Haemost. 2016 Jan;115(1):31-9. doi: 10.1160/TH15-04-0350. Epub 2015 Aug 6.
10
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
Zotero 插件